These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 14672496

  • 1. ACOG Committee Opinion. Use of progesterone to reduce preterm birth.
    American College of Obstetricians and Gynecologists.
    Obstet Gynecol; 2003 Nov; 102(5 Pt 1):1115-6. PubMed ID: 14672496
    [Abstract] [Full Text] [Related]

  • 2. Use of progesterone to reduce preterm birth.
    American College of Obstetrics and Gynecologist Committee Opinion.
    Int J Gynaecol Obstet; 2004 Jan; 84(1):93-4. PubMed ID: 14959752
    [Abstract] [Full Text] [Related]

  • 3. The rebirth of progesterone in the prevention of preterm labor.
    Schmouder VM, Prescott GM, Franco A, Fan-Havard P.
    Ann Pharmacother; 2013 Apr; 47(4):527-36. PubMed ID: 23535817
    [Abstract] [Full Text] [Related]

  • 4. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
    Manuck TA, Esplin MS, Biggio J, Bukowski R, Parry S, Zhang H, Huang H, Varner MW, Andrews W, Saade G, Sadovsky Y, Reddy UM, Ilekis J, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Genomics and Proteomics Network for Preterm Birth Research (GPN-PBR).
    Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Adherence rates and outcomes for 17-hydroxyprogesterone caproate use in women with a previous history of preterm birth.
    Edwards AM, Lowry SA, Mikovich S, Forinash AB, Babbar S.
    Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100166. PubMed ID: 33345885
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Recurrent hope for the treatment of preterm delivery.
    Doggrell SA.
    Expert Opin Pharmacother; 2003 Dec; 4(12):2363-6. PubMed ID: 14640934
    [Abstract] [Full Text] [Related]

  • 11. Does progesterone treatment influence risk factors for recurrent preterm delivery?
    Meis PJ, Klebanoff M, Dombrowski MP, Sibai BM, Leindecker S, Moawad AH, Northen A, Iams JD, Varner MW, Caritis SN, O'Sullivan MJ, Miodovnik M, Leveno KJ, Conway D, Wapner RJ, Carpenter M, Mercer B, Ramin SM, Thorp JM, Peaceman AM, Gabbe S.
    Obstet Gynecol; 2005 Sep; 106(3):557-61. PubMed ID: 16135587
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacological use of progesterone and 17-alpha-hydroxyprogesterone caproate in the prevention of preterm delivery.
    Facchinetti F, Vaccaro V.
    Minerva Ginecol; 2009 Oct; 61(5):401-9. PubMed ID: 19749671
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of 17α-hydroxyprogesterone caproate in prevention of preterm delivery.
    Saghafi N, Khadem N, Mohajeri T, Shakeri MT.
    J Obstet Gynaecol Res; 2011 Oct; 37(10):1342-5. PubMed ID: 21564406
    [Abstract] [Full Text] [Related]

  • 17. 17 α-hydroxyprogesterone caproate (Makena®): a guide to its use in the prevention of preterm birth.
    Hines M, Lyseng-Williamson KA, Deeks ED.
    Clin Drug Investig; 2013 Mar; 33(3):223-7. PubMed ID: 23413110
    [Abstract] [Full Text] [Related]

  • 18. Treatment options and recommendations to reduce preterm births in women with short cervix.
    Slager J, Lynne S.
    J Midwifery Womens Health; 2012 Jul; 57 Suppl 1():S12-8. PubMed ID: 22776244
    [Abstract] [Full Text] [Related]

  • 19. Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations.
    Feghali M, Venkataramanan R, Caritis S.
    Semin Perinatol; 2014 Dec; 38(8):516-22. PubMed ID: 25256193
    [Abstract] [Full Text] [Related]

  • 20. Salivary progesterone and estriol among pregnant women treated with 17-alpha-hydroxyprogesterone caproate or placebo.
    Klebanoff MA, Meis PJ, Dombrowski MP, Zhao Y, Moawad AH, Northen A, Sibai BM, Iams JD, Varner MW, Caritis SN, O'Sullivan MJ, Leveno KJ, Miodovnik M, Conway D, Wapner RJ, Carpenter M, Mercer BM, Ramin SM, Thorp JM, Peaceman AM, National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network.
    Am J Obstet Gynecol; 2008 Nov; 199(5):506.e1-7. PubMed ID: 18456237
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.